Pharmathene Inc., of Annapolis, Md., said it received a $20 million payment from Siga Technologies Inc., of New York, to extend by 90 days, until Oct. 19, the date by which Siga must satisfy the Pharmathene judgment. The payment is creditable against final satisfaction of the judgment in favor of Pharmathene of about $205 million plus interest and is not refundable. The judgment was awarded following a long-running dispute between the companies over smallpox antiviral tecovirimat. (See BioWorld Today, Aug. 12, 2014.)